| Valuation method | Value, CHF | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | 18.70 | -28 |
| Graham Formula | 0.30 | -99 |
RHÖN-KLINIKUM AG is a leading German healthcare provider specializing in in-patient, semi-patient, and outpatient medical services. Headquartered in Bad Neustadt an der Saale, the company operates eight hospitals with 5,420 beds across five medical sites, offering comprehensive treatment services in areas such as cardiovascular rehabilitation, hand surgery, neurology, psychosomatic medicine, addiction therapy, ophthalmology, trauma surgery, and thoracic and pulmonary care. RHÖN-KLINIKUM AG is a key player in Germany's healthcare sector, known for its specialized medical facilities and high-quality patient care. The company's focus on advanced treatments for complex conditions like tumors, spinal column disorders, and heart diseases positions it as a critical provider in the German healthcare landscape. With a strong operational footprint and a commitment to medical excellence, RHÖN-KLINIKUM AG continues to be a trusted name in European healthcare services.
RHÖN-KLINIKUM AG presents a stable investment opportunity within the healthcare sector, supported by its strong market position in Germany's hospital and rehabilitation services. The company's diversified medical offerings and consistent revenue stream (€1.6 billion in FY 2024) provide resilience against economic fluctuations, as evidenced by its low beta (0.099). However, the lack of dividend payouts may deter income-focused investors. While the company maintains a solid cash position (€279.9 million) and manageable debt (€149.6 million), its net income (€43.4 million) and diluted EPS (€0.65) suggest moderate profitability. Investors should weigh the stability of Germany's healthcare system against potential regulatory risks and competitive pressures in the hospital sector.
RHÖN-KLINIKUM AG competes in Germany's highly regulated and fragmented hospital market, where its key competitive advantages include specialized treatment centers (e.g., cardiovascular, neurology) and a strong regional presence in Bavaria and Hesse. The company benefits from Germany's universal healthcare system, ensuring steady patient inflows, but faces pricing pressure from public insurers. Its mid-sized scale (eight hospitals) allows for operational efficiency without the bureaucratic challenges of larger public hospital networks. However, it lacks the national footprint of market leaders like Fresenius Helios, limiting its bargaining power with suppliers. RHÖN-KLINIKUM's focus on rehabilitation and elective procedures differentiates it from acute-care-focused competitors, but this specialization also exposes it to demographic shifts and reimbursement policy changes. The company's low debt-to-equity ratio (≈18%) provides financial flexibility compared to more leveraged peers, though its growth prospects are constrained by Germany's restrictive hospital licensing system.